Systems and methods are provided for improving efficiency and quality of plasma being removed from a blood separation chamber. The system includes a separation chamber in which plasma is separated from cellular blood components, a pump for moving the plasma and an outlet line for removing the separated plasma from the blood separation chamber. An optical sensor assembly is configured to monitor the blood separation chamber and measure an interface position between the separated component and the plasma, and to generate an output indicative of the measured interface position. A controller is programmed to utilize a lipid concentration input of the blood and to set an original lipemia offset, a lipemia threshold and lipemia final setpoint from a predetermined database, and to use a proportional-integral-derivative control loop to assess the actual interface position plus the lipemia threshold to adjust and achieve a final lipemia setpoint for use during separation procedures.

Acoustophoretic devices are disclosed. The devices include a flow chamber, an ultrasonic transducer, a reflector, an inlet, a filtrate outlet, a concentrate outlet, and optionally a lipid collection trap. The ultrasonic transducer and reflector create a multi-dimensional acoustic standing wave in the flow chamber that traps and separates red blood cells and/or lipids from blood. Concentrated red blood cells can be recovered via the concentrate outlet, the lipids can be recovered via the lipid collection trap, and the remaining blood can be recovered via the filtrate outlet. Methods for separating blood components (e.g., red blood cells, lipids, platelets, white blood cells) from blood are also disclosed. The red blood cells can undergo washing with a solvent to remove undesired admixtures. Cryoprotectants can be added or removed from the blood.

The present specification is directed to systems, apparatus and methods for treating lipid-related diseases including homozygous familial hypercholesterolemia, heterozygous familial hypercholesterolemia, ischemic stroke, coronary artery disease, acute coronary syndrome, peripheral arterial disease, or renal arterial disease and its complications, and for treating the progression of Alzheimer's disease using imaging techniques to assess changes in one or more lipid-containing atheroma areas and volumes after serial infusions of delipidated plasma as compared to a baseline

The present specification is directed to systems, apparatus and methods for treating lipid-related diseases including homozygous familial hypercholesterolemia, heterozygous familial hypercholesterolemia, ischemic stroke, coronary artery disease, acute coronary syndrome, peripheral arterial disease, or renal arterial disease and its complications, and for treating the progression of Alzheimer's disease using imaging techniques to assess changes in one or more lipid-containing atheroma areas and volumes after serial infusions of delipidated plasma as compared to a baseline

A detoxification method for treating sepsis, microbial infections, and other inflammatory conditions includes the steps of inducing flow of patient blood through a blood treatment device consisting of a bioreactor inlet and outlet in fluid connection to the circulatory system of a patient. Biological agents including lipopolysaccharide (LPS) and extracellular adenosine triphosphate (ATP) contained within patient blood can be irreversibly detoxified by passage of patient blood over a bioreactor surface having attached or immobilized alkaline phosphatase enzymes and acyloxyacyl hydrolase enzyme, with the bioreactor being contained within the blood treatment device. The method uses continuous treatment of a patient's blood to convert LPS and extracellular ATP in blood into inhibitors of inflammation in vivo without adding any chemicals to the bloodstream of the patient.

Embodiments of the invention relate to an extracorporeal perfusion apparatus comprising an extracorporeal blood circuit for conveying blood, a filtrate circuit for conveying blood plasma, and a controller, wherein the filtrate circuit is connected to the extracorporeal blood circuit by means of a filter, wherein the filter has a sieving coefficient of 5% for substances having a molar mass of 340,000 g/mol (relative molecular mass of 340 kDa), and wherein a depletion agent comprising a first carrier having a neutral, hydrophobic surface is arranged in the filtrate circuit, wherein the perfusion apparatus comprises a dispensing means for feeding an endotoxin-binding lipopeptide into the extracorporeal blood circuit, wherein the endotoxin-binding lipopeptide is selected from the group consisting of polymyxins, polymyxin derivatives, prodrugs thereof, and a combination thereof.

Acoustophoretic devices are disclosed. The devices include a flow chamber, an ultrasonic transducer, a reflector, an inlet, a filtrate outlet, a concentrate outlet, and optionally a lipid collection trap. The ultrasonic transducer and reflector create a multi-dimensional acoustic standing wave in the flow chamber that traps and separates red blood cells and/or lipids from blood. Concentrated red blood cells can be recovered via the concentrate outlet, the lipids can be recovered via the lipid collection trap, and the remaining blood can be recovered via the filtrate outlet. Methods for separating blood components (e.g., red blood cells, lipids, platelets, white blood cells) from blood are also disclosed. The red blood cells can undergo washing with a solvent to remove undesired admixtures. Cryoprotectants can be added or removed from the blood.